Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Comparing the Efficacy and Safety of Optimized rhTPO Treatment Versus Eltrombopag Treatment in Previously Treated Primary Immune Thrombocytopenia Patients: A Multicenter Randomized Open-label Trial

NCT05583838 is registered in ClinicalTrials.gov with Institute of Hematology & Blood Diseases Hospital, China as lead sponsor.

NCT NCT05583838
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05583838 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Comparing the Efficacy and Safety of Optimized rhTPO Treatment Versus Eltrombopag Treatment in Previously Treated Primary Immune Thrombocytopenia Patients: A Multicenter Randomized Open-label Trial
Lead sponsor
Institute of Hematology & Blood Diseases Hospital, China
Phase
Phase 4
Overall status
Completed
Start date
November 22, 2022
Completion date
July 16, 2024
Enrollment
157 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

previously treated primary immune thrombocytopenia